Shaping the Future of Cancer Care: Inside the Cardiff Cancer Research Hub

The impact on patients and families

Patients and their families in Wales are beginning to see meaningful improvements in cancer care, thanks to a growing focus on research-driven innovation. One of the key goals is to significantly increase access to cutting-edge cancer trials for Welsh patients. By attracting more clinical trials to Wales, especially those funded by industry or involving multiple organisations, more patients have the opportunity to benefit from the latest advances in treatment without needing to travel far from home.

This surge in research activity is the result of strong collaboration between academics and clinicians who are working hand-in-hand to design and deliver complex studies. These partnerships are helping to fast-track the discoveries from laboratory research into real-world treatments through a more efficient “bench-to-bedside” approach. The result is a research pipeline that not only meets the growing demand from patients but also aligns with the needs of the pharmaceutical industry for innovative, trial-ready environments.

Importantly, this research expansion is also helping to tackle health inequalities. By ensuring that clinical trials are accessible across Wales, the initiative is reducing disparities in cancer care and giving all patients an equal chance to benefit from research breakthroughs.

At the heart of this transformation is a commitment to building capacity for the future. Investment in staffing and infrastructure is enabling Wales to support more complex, high-quality clinical trials. At the same time, efforts to grow a future-focused research workforce, by increasing the number of clinical academics and making it easier to carry out research across the NHS and academic sectors we are laying the foundation for continued progress. Together, these changes are helping to deliver better outcomes for cancer patients and their families, and positioning Wales as a leader in bold, innovative research in both solid tumour and haematology care.